Biora Therapeutics Home
Activate the mobile navigation
Close the mobile navigation
Close
Home
Company
About
Leadership
Careers
Pipeline
Development Pipeline
Targeted Therapeutics
Systemic Therapeutics
Publications
Investors
Investor Overview
Press Releases
Events & Presentations
SEC Filings
Annual & Quarterly Reports
Stock Quote & Chart
Historical Price Lookup
Analyst Coverage
Governance Documents
Committee Composition
Investor FAQs
Investor Email Alerts
Investor Relations Contact
Contact
Toggle the search bar
Search the Site
Close the mobile navigation
Publications
Select Category
Select Category...
Gastrointestinal Health
Systemic Therapeutics
Targeted Therapeutics
A novel method for collecting microbiome specimens: proof of concept in normal healthy volunteers
May 24, 2022
#Gastrointestinal Health
Pharmacokinetic stratification of cytokine profiles during anti-TNF induction treatment in moderate-to-severe ulcerative colitis
May 24, 2022
#Targeted Therapeutics
Tofacitinib tissue exposure correlates with endoscopic outcome
May 22, 2022
#Targeted Therapeutics
Development of a novel drug delivery system to deliver drugs directly to the colonic mucosa
July 7, 2021
#Targeted Therapeutics
Development of a novel drug delivery system for targeted treatment of ulcerative colitis
May 20, 2021
#Targeted Therapeutics
Targeted delivery of tofacitinib citrate to the site of disease to improve efficacy and safety
May 20, 2021
#Targeted Therapeutics
Evaluation of novel lab-in-a-capsule technology for SIBO diagnosis
November 23, 2020
#Gastrointestinal Health
SIBO diagnosis: clinical survey of practice patterns, unmet needs, and perception of a novel ingestible diagnostic capsule
November 9, 2020
#Gastrointestinal Health
Targeted topical anti-α4β7 integrin antibody results in reduced accumulation of α4β7 memory T-cells in gut tissue in DSS-induced colitis mice
October 28, 2019
#Targeted Therapeutics
1
2
3
Connect with us
Email Us
Biora Therapeutics Linkedin
Biora Therapeutics Twitter